HubSpot: Short-Term Pain, Mispriced Recovery (NYSE:HUBS)
· seekingalpha.com
HubSpot remains a buy, with an 18% FY 2027 upside target, despite a recent -46% YTD decline and market overreaction to AI disruption fears. Read more on HUBS.
HubSpot ( HUBS ) is a company I am familiar with. I published my analysis for the first time here back in November 2019, and revisited it during COVID-19 in mid...